Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.53+0.67 (+4.51%)
Close on Nov 18, 2026Market cap $708.96MP/E –Yield –
Attovia Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$22.27M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.15M | – |
See a number that looks wrong?